Department of Cardiovascular Disease, University of Rome-Tor Vergata, Rome, Italy.
Am Heart J. 2013 May;165(5):679-92. doi: 10.1016/j.ahj.2013.02.020. Epub 2013 Mar 26.
Despite the recommendations of the current guidelines, scientific evidence continue to challenge the effectiveness of intra-aortic balloon pump (IABP) in acute myocardial infarction (AMI) complicated by cardiogenic shock. Moreover, 2 recent meta-analyses showed contrasting results. The aim of this study is to test the effect of IABP according to the type of therapeutic treatment of AMI: percutaneous coronary intervention (PCI), thrombolytic therapy (TT), or medical therapy without reperfusion. Articles published from January 1, 1986, to December 31, 2012, were collected and analyzed by meta-analysis.
We evaluated the IABP impact on inhospital mortality, on safety end points (stroke, severe bleeding) and long-term survival, using risk ratio (RR) and risk difference (RD) estimates. We found that the risk of death was (i) not significantly different between the IABP and control groups (RR 0.95, P = .52; RD -0.04, P = .28), (ii) significantly reduced in the TT subgroup (RR 0.77, P < .0001; RD -0.16, P < .0001), and (iii) significantly increased in the PCI subgroup (RR 1.18, P = .01; RD 0.07, P = .01). There were no significant differences in secondary end points (P, not significant). In addition, we compared the meta-analyses collected over the same search period.
The results show that IABP support is significantly effective in TT reperfusion but is associated with a significant increase of the inhospital mortality with primary PCI. The comparison of the meta-analyses demonstrates the key role of analysing primary clinical treatments to avoid systematic errors.
尽管当前指南有相关推荐,但是科学证据仍在不断挑战主动脉内球囊反搏(IABP)在伴心源性休克的急性心肌梗死(AMI)中的有效性。此外,最近的两项荟萃分析结果显示出相互矛盾的结果。本研究旨在根据 AMI 的治疗方法(经皮冠状动脉介入治疗(PCI)、溶栓治疗(TT)或无再灌注的药物治疗)来检验 IABP 的效果。从 1986 年 1 月 1 日至 2012 年 12 月 31 日,收集并分析发表的文章,采用风险比(RR)和风险差(RD)评估。
我们评估了 IABP 对住院死亡率、安全性终点(卒中、严重出血)和长期生存的影响,使用风险比(RR)和风险差(RD)估计值。我们发现,IABP 与对照组之间的死亡率(i)无显著差异(RR 0.95,P =.52;RD -0.04,P =.28),(ii)在 TT 亚组中显著降低(RR 0.77,P <.0001;RD -0.16,P <.0001),(iii)在 PCI 亚组中显著增加(RR 1.18,P =.01;RD 0.07,P =.01)。次要终点无显著差异(P,无统计学意义)。此外,我们比较了在同一检索期间收集的荟萃分析。
结果表明,IABP 支持在 TT 再灌注中具有显著疗效,但与主要 PCI 相关的住院死亡率显著增加相关。荟萃分析的比较表明,分析主要临床治疗方法以避免系统误差至关重要。